Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May-Jun;43(3):263-266.
doi: 10.1097/JCP.0000000000001688.

A Study of Cardiac Outcomes After Droperidol Administration in an Inpatient Psychiatric Cohort

Tim Zong Tian Yang  1 , Chen Lew  2 , Anushi Thathsara Ilangamage  2 , Robert Donald Gillies  1 , Jayashri Kulkarni  3
Affiliations

A Study of Cardiac Outcomes After Droperidol Administration in an Inpatient Psychiatric Cohort

Tim Zong Tian Yang et al. J Clin Psychopharmacol. 2023 May-Jun.

Abstract

Purpose/background: Droperidol is an antipsychotic medication used in psychiatric emergencies to manage acute behavioral disturbance. Droperidol use carries a risk of prolonged QT interval on the electrocardiogram and associated cardiac arrhythmias including torsades de pointes and ventricular fibrillation. This study aimed to evaluate the safety of droperidol in adults admitted to the psychiatric inpatient unit of a large Australian hospital.

Methods/procedures: In this retrospective cohort study, psychiatric inpatients admitted between October 22, 2018, and March 1, 2021, who received at least 1 dose of intramuscular droperidol were consecutively included. Outcomes of interest were death, cardiac arrhythmias, and QT prolongation. QT prolongation was identified using the QT-interval nomogram.

Findings/results: This study included 263 patients without exclusion. No deaths or cases of cardiac arrhythmia were recorded within 24 hours of droperidol administration. Electrocardiogram data were available for 41.1% of patients (n = 108) within 7 days of droperidol administration. Two cases of QT prolongation were identified using the QT-interval nomogram, but these patients were also prescribed other medications that may have contributed to QT prolongation.

Implications/conclusions: This study contributes the first known large retrospective study of safety outcomes including QT prolongation after droperidol administration in a psychiatric inpatient setting. Our findings corroborate mounting evidence supporting the clinical safety of droperidol use in psychiatric settings. Nonetheless, we note that significant barriers remain with regard to timely electrocardiogram monitoring after droperidol use.

PubMed Disclaimer

References

    1. Kao LW, Kirk MA, Evers SJ, et al. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med . 2003;41:546–558.
    1. Foo LK, Duffull SB, Calver L, et al. Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. Br J Clin Pharmacol . 2016;82:1550–1556.
    1. Guy JM, André-Fouet X, Porte J, et al. Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol. Ann Cardiol Angeiol (Paris) . 1991;40:541–545.
    1. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg . 1994;79:983–986.
    1. Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm . 2007;64:1174–1186.

LinkOut - more resources